Corcept Therapeutics (CORT) Revenue (2012 - 2026)
Corcept Therapeutics recorded quarterly Revenue of $164.9 million in Q1 2026, down 18.42% quarter-over-quarter from $202.1 million in Q4 2025, and up 4.89% year-over-year from $157.2 million in Q1 2025.
Corcept Therapeutics' Revenue history runs 15 years deep, the most recent figure standing at $164.9 million for Q1 2026.
- In Q1 2026, Revenue rose 4.89% year-over-year to $164.9 million; the TTM figure through Mar 2026 stood at $769.1 million (up 12.2% YoY), while the FY2025 annual figure was $761.4 million, up 12.79% from the prior year.
- Revenue came in at $164.9 million for Q1 2026 at Corcept Therapeutics, down from $202.1 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $207.6 million in Q3 2025 to a low of $93.7 million in Q1 2022.
- A 5-year average of $146.2 million and a median of $146.8 million in 2024 frame the typical range for Revenue.
- Across the five-year window, Revenue grew 4.28% in 2022 and surged 47.69% in 2024, its largest moves.
- Corcept Therapeutics' Revenue stood at $103.1 million in 2022, then soared by 31.39% to $135.4 million in 2023, then surged by 34.33% to $181.9 million in 2024, then advanced by 11.12% to $202.1 million in 2025, then declined by 18.42% to $164.9 million in 2026.
- According to Business Quant data, Revenue over the past three periods registered $164.9 million, $202.1 million, and $207.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 306.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 2.99 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 3.61 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1.17 Bn |
| 10 | Corcept Therapeutics | 7.26 Bn | 6.92 Bn | 162.02 Mn | 164.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 164.90 Mn |
| Dec 31, 2025 | 202.13 Mn |
| Sep 30, 2025 | 207.64 Mn |
| Jun 30, 2025 | 194.43 Mn |
| Mar 31, 2025 | 157.21 Mn |
| Dec 31, 2024 | 181.89 Mn |
| Sep 30, 2024 | 182.55 Mn |
| Jun 30, 2024 | 163.80 Mn |
| Mar 31, 2024 | 146.81 Mn |
| Dec 31, 2023 | 135.41 Mn |
| Sep 30, 2023 | 123.60 Mn |
| Jun 30, 2023 | 117.72 Mn |
| Mar 31, 2023 | 105.65 Mn |
| Dec 31, 2022 | 103.06 Mn |
| Sep 30, 2022 | 101.73 Mn |
| Jun 30, 2022 | 103.39 Mn |
| Mar 31, 2022 | 93.69 Mn |
| Dec 31, 2021 | 98.82 Mn |
| Sep 30, 2021 | 96.13 Mn |
| Jun 30, 2021 | 91.59 Mn |
| Mar 31, 2021 | 79.44 Mn |
| Dec 31, 2020 | 85.74 Mn |
| Sep 30, 2020 | 86.33 Mn |
| Jun 30, 2020 | 88.57 Mn |
| Mar 31, 2020 | 93.25 Mn |
| Dec 31, 2019 | 87.90 Mn |
| Sep 30, 2019 | 81.51 Mn |
| Jun 30, 2019 | 72.26 Mn |
| Mar 31, 2019 | 64.83 Mn |
| Dec 31, 2018 | 66.83 Mn |
| Sep 30, 2018 | 64.45 Mn |
| Jun 30, 2018 | 62.31 Mn |
| Mar 31, 2018 | 57.66 Mn |
| Dec 31, 2017 | 53.28 Mn |
| Sep 30, 2017 | 42.76 Mn |
| Jun 30, 2017 | 35.56 Mn |
| Mar 31, 2017 | 27.60 Mn |
| Dec 31, 2016 | 23.81 Mn |
| Sep 30, 2016 | 21.73 Mn |
| Jun 30, 2016 | 19.72 Mn |
| Mar 31, 2016 | 16.06 Mn |
| Dec 31, 2015 | 14.97 Mn |
| Sep 30, 2015 | 13.26 Mn |
| Jun 30, 2015 | 11.96 Mn |
| Mar 31, 2015 | 10.10 Mn |
| Dec 31, 2014 | 9.01 Mn |
| Sep 30, 2014 | 7.28 Mn |
| Jun 30, 2014 | 5.85 Mn |
| Mar 31, 2014 | 4.41 Mn |
| Dec 31, 2013 | 4.12 Mn |
| Sep 30, 2013 | 2.63 Mn |
| Jun 30, 2013 | 1.89 Mn |
| Mar 31, 2013 | 1.72 Mn |
| Dec 31, 2012 | 1.38 Mn |
| Sep 30, 2012 | 1.06 Mn |
| Jun 30, 2012 | 875,000.00 |